47 results on '"Bekaii-Saab, Tanios"'
Search Results
2. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience
3. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy
4. Isocitrate Dehydrogenase–Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes
5. Isocitrate Dehydrogenase–Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes
6. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study
7. Osteoclast-Like Giant Cell Tumors of the Pancreas: Clinical Characteristics, Genetic Testing, and Treatment Modalities
8. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma
9. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience
10. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma
11. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States
12. Development and Validation of a Nomogram for Early Detection of Malignant Gallbladder Lesions
13. Antiangiogenic Therapy in Colorectal Cancer
14. Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience
15. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
16. Incidence and Survival of Appendiceal Mucinous Neoplasms: A SEER Analysis
17. Perineural Invasion Predicts for Distant Metastasis in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation and Surgery
18. The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy
19. Second‐line treatment in patients with pancreatic ductal adenocarcinoma: A meta‐analysis
20. Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia
21. Predictors of Pancreatic Cancer–Associated Weight Loss and Nutritional Interventions
22. Therapeutic Advances in Pancreatic Cancer: Miles to Go Before We Sleep
23. Incidence of Minimally Invasive Colorectal Cancer Surgery at National Comprehensive Cancer Network Centers
24. Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil–Induced Cardiac Vasospasm
25. Maintenance Therapy for Colorectal Cancer: Which Regimen and Which Patients?
26. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells
27. Pain, Depression, and Fatigue: Loneliness as a Longitudinal Risk Factor
28. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study†
29. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab
30. Processes of Care in the Multidisciplinary Treatment of Gastric Cancer: Results of a RAND/UCLA Expert Panel
31. Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer
32. RAS mutations: impact on treatment outcome
33. A Phase I Dose Escalation and Pharmacodynamic Study of SU5416 (Semaxanib) Combined with Weekly Cisplatin and Irinotecan in Patients with Advanced Solid Tumors
34. What provider volumes and characteristics are appropriate for gastric cancer resection? Results of an international RAND/UCLA expert panel
35. A Multi-Institutional Phase 2 Study of Neoadjuvant Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
36. Carbohydrate antigen 19–9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: A pooled analysis of 6 prospective trials
37. Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma
38. Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial
39. Yttrium-90 Radioembolization as Salvage Therapy for Colorectal Cancer With Liver Metastases
40. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors
41. Recurrent Life-Threatening Deep Tissue Hematomas After Switching to Generic Enoxaparin: A Report and Perspective on the Approval Process for Biological Compounds
42. A phase I study of topotecan and gemcitabine in advanced solid tumors
43. Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer
44. Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma
45. KRAS Testing in Metastatic Colorectal Cancer: Implications on the Use of Biologic Agents
46. Incorporation of Photodynamic Therapy as an Induction Modality in Non-Small Cell Lung Cancer
47. A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.